Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ono Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NSCLC patients | Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Description of clinical usage of nivolumab in previously treated NSCLC patients | Approximately 9 months | |
| Overall Survival (OS) | Measured from time of initial diagnosis and treatment with nivolumab until date of death | Approximately 9 months |
| Progression Free Survival (PFS) | Time since index date (initial diagnosis and treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first | Approximately 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients receiving bi-weekly nivolumab | Approximately 9 months | |
| Percentage of patients receiving monotherapy or combination therapy | Approximately 9 months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients who meets the inclusion criteria will be included in the analysis to describe real-world clinical usage of nivolumab. However, patients treated with nivolumab falling in following criteria will be excluded for analysis for the other primary endpoint; overall effectiveness:
Other protocol defined inclusion/exclusion criteria could apply
Not provided
Not provided
Not provided
Not provided
Previously treated advanced/metastatic NSCLC patients treated with nivolumab in Japan.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Minato-ku | Tokyo | 1050001 | Japan |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| Investigator Inquiry Form | View source |
| FDA Safety Alerts and Recalls |
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Percentage of patients receiving nivolumab as second or later line of therapy |
| Approximately 9 months |
| Median treatment duration and range by line and histology | Approximately 9 months |
| Rate of permanent and temporary discontinuations | Approximately 9 months |
| Reasons for discontinuation of nivolumab | Approximately 9 months |
| Reasons for re-challenge of nivolumab | Approximately 9 months |
| Objective Response Rate (ORR) as assessed by investigator | ORR is defined as the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the total number of participants who received treatment | Approximately 9 months |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |